Clinical Study Demonstrated the Effectiveness of New Weight Loss Tablet

• Eli Lilly presented the results of a clinical study of a weight loss tablet.
• The tablet helped reduce weight by an average of 10.5% in patients with diabetes.
• It is expected that the drug will be approved by the end of 2025.

Eli Lilly announced the successful results of its clinical study of its new weight loss tablet, which helped adults with type 2 diabetes lose an average of 10.5% of body weight over 72 weeks. The study involved more than 1,600 participants, who received the highest dose of 36 milligrams of the drug orforglipron.

The tablet also demonstrated a reduction in A1C levels, which is an indicator of average blood sugar levels, in 75% of patients who received the highest dose. Eli Lilly believes that the tablet could be a more convenient alternative to injectable drugs for weight loss, such as Zepbound and Wegovy.

During the study, participants who received the tablet lost an average of 23 pounds (approximately 10.4 kg), while the placebo group lost only 2.2%. In addition to weight loss, improvements were observed in cardiovascular risk indicators, including reduced cholesterol levels, triglycerides, and arterial pressure.

The head of the cardiometabolic health company noted that the tablet could be approved by the FDA for the treatment of obesity by the end of 2025. Eli Lilly also plans to present data for review in other regulators.

The study showed that common side effects, such as nausea and vomiting, were similar to those experienced by patients who received injectable drugs. According to the company, no problems with safety were identified.

Tags: Well-being/Research